NASDAQ$RPRX
Royalty Pharma PLC · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Royalty Pharma reported second quarter 2024 financial results with portfolio receipts growth and raised full year guidance.
Royalty Pharma reported a 12% increase in Portfolio Receipts, reaching $608 million, and an 11% increase in Royalty Receipts. The company also raised its full-year 2024 guidance for Portfolio Receipts to $2,700 to $2,775 million. Capital deployment was approximately $2 billion in 2024.
- Portfolio Receipts grew by 12% to $608 million.
- Royalty Receipts increased by 11%.
- Net cash provided by operating activities was $658 million.
- Full year 2024 guidance for Portfolio Receipts was raised to $2,700 to $2,775 million.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$537M
Revenue by segment
Royalty Pharma · $687M total across 13 segments · Q3 2023
- Cystic Fibrosis Franchise$238M+14.4%34.6%
- Tysabri$87M-4.4%12.7%
- Imbruvica$62M-16.2%9.0%
- Trelegy$58M+34.9%8.4%
- Promacta$54M+8.0%7.9%
- Xtandi$47M+2.2%6.8%
- Other Products$46M-37.0%6.7%
- Tremfya$27M+28.6%3.9%
- Cabometyx/Cometriq$17M+13.3%2.5%
- Evrysdi$16M+60.0%2.3%
- Spinraza$15M—2.2%
- Trodelvy$11M+83.3%1.6%
- Erleada$9M+50.0%1.3%
Forward guidance
Royalty Pharma expects 2024 Portfolio Receipts to be between $2,700 million and $2,775 million, which includes expected Royalty Receipts growth of 9% to 12%.
Tailwinds
- Portfolio Receipts are expected to be between $2,700 million and $2,775 million.
- Royalty Receipts are expected to grow 9% to 12% in 2024.
- Guidance excludes contributions from future transactions.
- Guidance assumes no major unforeseen adverse events.
- Guidance reflects a negligible estimated foreign exchange impact.
Headwinds
- Guidance excludes transactions and borrowings announced after the date of the release.
- Guidance may be amended in the event of new royalty transactions with a material near-term financial impact.
- Total interest paid is anticipated to be approximately $160 million in 2024.
- Interest paid is anticipated to be approximately $79 million in the third quarter of 2024 with a de minimis amount being recorded in the fourth quarter of 2024.
- Projection assumes no additional debt financing in 2024, including no drawdown on the revolving credit facility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro